Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2095188 Target Snapshot

Glycogen synthase kinase-3 · PROTEIN FAMILY · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
717Compounds
112Assays
0Approved Drugs
700.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Glycogen synthase kinase-3 shows approved-linked disease relevance led by bipolar I disorder. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P49840. Start with bipolar I disorder, then reuse UniProt P49840 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with bipolar I disorder, then reuse UniProt P49840 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 2 linked drugs
Open source guide
Disease program
bipolar I disorder

Glycogen synthase kinase-3 shows approved-linked disease relevance led by bipolar I disorder. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with bipolar I disorder because it currently carries approved-linked support. Linked drugs include LITHIUM CARBONATE, LITHIUM CITRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Glycogen synthase kinase-3 as ChEMBL target CHEMBL2095188, mapped to UniProt P49840. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Glycogen synthase kinase-3
PROTEIN FAMILY · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2095188
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P49840
Glycogen synthase kinase-3 alpha
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Glycogen synthase kinase-3 is the right protein anchor across sources, using UniProt P49840 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why bipolar I disorder is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameGlycogen synthase kinase-3
Target TypePROTEIN FAMILY
OrganismHomo sapiens
UniProtP49840
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelGlycogen synthase kinase-3 alpha
UniProt AccessionP49840
Component TypeProtein
Sequence Length483 aa

Glycogen synthase kinase-3 alpha

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Glycogen synthase kinase-3, mapped to UniProt P49840. ChEMBL maps the protein component as Glycogen synthase kinase-3 alpha. Sequence length is 483 aa.

Mapped IDP49840
Review nameGlycogen synthase kinase-3
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Glycogen synthase kinase-3 shows approved-linked disease relevance led by bipolar I disorder. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
bipolar I disorder
2 linked drugs · 2 direct · 2 efficacy
Linked drugLITHIUM CARBONATE
Linked drugLITHIUM CITRATE
Approved-linked Approved
bipolar disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugLITHIUM CARBONATE
Approved-linked Approved
depressive disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugLITHIUM CARBONATE
Approved-linked Approved
major depressive disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugLITHIUM CARBONATE
Late clinical Phase III
aggressive behavior
1 linked drug · 1 direct · 1 efficacy
Linked drugLITHIUM CARBONATE
Late clinical Phase III
alcohol dependence
1 linked drug · 1 direct · 1 efficacy
Linked drugLITHIUM CARBONATE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with bipolar I disorder because it currently carries approved-linked support. Linked drugs include LITHIUM CARBONATE, LITHIUM CITRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasebipolar I disorder
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

4
Phase III
4
Phase II
3
Phase I
Assay Mix

Activity Type Distribution

IC50653.0
KI34.0
EC5013.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5174733 9.22 Ki 0.6 Preclinical
CHEMBL178766 9.1 IC50 0.8 Preclinical
CHEMBL181339 9.1 IC50 0.8 Preclinical
CHEMBL181371 9.05 IC50 0.9 Preclinical
CHEMBL181518 9.0 IC50 1.0 Preclinical
CHEMBL359871 8.96 IC50 1.1 Preclinical
CHEMBL180779 8.92 IC50 1.2 Preclinical
CHEMBL178737 8.89 IC50 1.3 Preclinical
CHEMBL3216659 8.89 IC50 1.3 Preclinical
CHEMBL369090 8.89 IC50 1.3 Preclinical
Distribution

pChEMBL Value Distribution

70
5.0
63
5.5
82
6.0
68
6.5
56
7.0
45
7.5
44
8.0
24
8.5
5
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

112
Total Assays
480
Tested Compounds
2
Assay Types
Binding — 105 assays, 480 compounds
BAO Format Assays Compounds Avg pChEMBL
protein format 73 343 6.4
cell-based format 25 38 7.1
assay format 6 90 6.7
tissue-based format 1 9 7.2
Functional — 7 assays, 10 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 7 10 6.2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine